Association of lung cancer with ALK and EGFR and its targeted therapy
DOI:
https://doi.org/10.54097/hset.v36i.5731Keywords:
Lung Cancer, ALK, EGFR, Targeted Therapy.Abstract
As one of the diseases that are extremely harmful to human health, cancer is difficult to treat and has a high mortality rate. And Lung cancer is the most common disease in the world and the type of cancer with the highest mortality rate. In order to better understand and monitor the incidence and mortality of cancer and trends as well as the prevention and treatment of lung cancer. In terms of modern medical technology, the treatment of lung cancer is mainly divided into local treatment and systemic treatment, the main method of local treatment is surgery and radiotherapy, and systematic treatment is a drug-based treatment mode, but because lung cancer cells may still remain in the body after treatment. Over time, these cells may divide and grow. How to achieve thorough treatment of lung cancer is a difficult problem to be overcome.
Downloads
References
Thorac Cancer. 2018 Apr; 9(4): 423–430. Published online 2018 Feb 28. doi: 10.1111/1759-7714.12613
J Clin Oncol. 2018 Apr 20; 36(12): 1199–1206. Published online 2018 Jan 26. doi: 10.1200/JCO.2017.76.2294
Eichenmuller B, Everley P, Palange J, Lepley D, Suprenant KA. The human EMAP-like protein-70 (ELP70) is a microtubule destabilizer that localizes to the mitotic apparatus. J Biol Chem. 2002 Jan 11;277(2):1301-9. doi: 10.1074/jbc.M106628200. Epub 2001 Nov 2. PMID: 11694528.
Clin Cancer Res. Author manuscript; available in PMC 2011 Jan 24. Published in final edited form as: Clin Cancer Res. 2008 Jul 1; 14(13): 4275–4283. doi: 10.1158/1078-0432.CCR-08-0168
Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014 Jan;79:34-74. DOI: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20. PMID: 24269963.
Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020 Apr;61:167-179. DOI: 10.1016/j.semcancer.2019.09.015. Epub 2019 Sep 25. PMID: 31562956; PMCID: PMC7083237.
Matsui T, Tanizawa Y, Enatsu S. [Exon 19 Deletion and Exon 21 L858R Point Mutation in EGFR Mutation‒Positive Non‒Small Cell Lung Cancer]. Gan To Kagaku Ryoho. 2021 May;48(5):673-676. Japanese. PMID: 34006711.
Li AM, Boichard A, Felip E, Kurzrock R. New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. Crit Rev Oncol Hematol. 2020 Jul;151:102990. DOI: 10.1016/j.critrevonc.2020.102990. Epub 2020 May 20. PMID: 32485428; PMCID: PMC7416421.
Yang X, Zhao J. [Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations]. Zhongguo Fei Ai Za Zhi. 2022 May 20;25(5):337-350. Chinese. DOI: 10.3779/j.issn.1009-3419.2022.103.01. PMID: 35599009; PMCID: PMC9127758.
Tao JIANG, Caicun ZHOU. Treatment of Patients with ALK Gene Rearranged Non-small Cell Lung Cancer after Resistance to Crizotinib [J]. Chinese Journal of Lung Cancer,2015(2):69-74. DOI:10.3779/j.issn.1009-3419.2015.02.03.
Aiping HOU. Research progress of targeted medicine for non-small cell lung cancer withr epidermal growth factor receptor mutation [J]. Contemporary Medicine,2022,28(15):181-186. DOI:10.3969/j.issn.1009-4393.2022.15.063.
Yan ZHAO, Ru ZHANG. The Mechanism and Therapy Perspective of Erlotinib in Patients with Non-small Cell Lung Cancer [J]. Chinese Journal of Pharmacovigilance,2010,7(10):617-619. DOI:10.3969/j.issn.1672-8629.2010.10.014.
Haiqiong LI. Research Progress of Afatinib for Treating Non-Small Cell Lung Cancer [J]. China Pharmaceuticals,2017,26(19):5-8. DOI:10.3969/j.issn.1006-4931.2017.19.002.
Jun CHEN, Jiali HUANG, Zhixiang CHENG. Progress of Ositinib for Treating Advanced Non-Small Cell Lung Cancer [J]. Journal of Southeast University(Medical Science Edition),2020,39(1):85-89. DOI:10.3969/j.issn.1671-6264.2020.01.019.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
